Bioxytran Launches Joint Venture with the Heme Foundation for Development of Universal Oxygen Carrier
18. Juli 2024 09:00 ET
|
BIOXYTRAN, INC.
The Heme Foundation and Bioxytran join forces to address the global blood supply shortage BOSTON, MASSACHUSETTS, July 18, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a...
Bioxytran’s Advisor Releases Book on Hyperbaric Oxygenation Related to Stroke & Alzheimer’s Patients
27. Juni 2024 13:09 ET
|
BIOXYTRAN, INC.
BXT-25 is expected to oxygenate the brain BOSTON, MASSACHUSETTS, June 27, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing...
Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19
21. Februar 2024 08:00 ET
|
BIOXYTRAN, INC.
First Medicinal chemistry of an antiviral drug made of sugars BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT), (the “Company”), a clinical stage biotechnology...
Bioxytran Interview at the Emerging Growth Conference
04. Oktober 2023 09:00 ET
|
BIOXYTRAN, INC.
Thursday, October 5, 2023 10:15 am –10:45 am ESTSmall Pharma Strategy BOSTON, MASSACHUSETTS, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage...
Bioxytran Interview at the Emerging Growth Conference
01. Mai 2023 08:00 ET
|
BIOXYTRAN, INC.
Wednesday, May 3, 2023 12:35 pm –1:05 pm ESTMedical/Scientific Community Reaction to Peer Reviewed Article BOSTON, MASSACHUSETTS, May 01, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT)...
Bioxytran Interview at the Emerging Growth Conference
03. April 2023 15:04 ET
|
BIOXYTRAN, INC.
Wednesday, April 5, 2023 10:50 am –11:20am ESTDiscussion of Peer Reviewed Article and Long COVID BOSTON, MASSACHUSETTS, April 03, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the...
ProLectin-M Demonstrates Significant Activity Against Influenza and Respiratory Syncytial Virus
28. Februar 2023 08:00 ET
|
BIOXYTRAN, INC.
Activity in Influenza and Respiratory Syncytial Virus highlights the broad- spectrum antiviral potential of ProLectin-M BOSTON, MASSACHUSETTS, Feb. 28, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC....
Nature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral Drug
22. Februar 2023 08:00 ET
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat...
Bioxytran to Appear on ClearThink IR’s Virtual Live Event
14. Februar 2023 09:00 ET
|
BIOXYTRAN, INC.
- Wednesday, February 15th, 2023 12:00 EST - Virtual Fireside Chat via Paltalk Platform BOSTON, MASSACHUSETTS, Feb. 14, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”),...
Bioxytran Receives Approval to Initiate Trials with ProLectin-I
06. Februar 2023 09:00 ET
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Feb. 06, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19...